JP2020504607A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020504607A5 JP2020504607A5 JP2019533514A JP2019533514A JP2020504607A5 JP 2020504607 A5 JP2020504607 A5 JP 2020504607A5 JP 2019533514 A JP2019533514 A JP 2019533514A JP 2019533514 A JP2019533514 A JP 2019533514A JP 2020504607 A5 JP2020504607 A5 JP 2020504607A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- domain
- cdr
- amino acid
- adam9
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940127121 immunoconjugate Drugs 0.000 claims description 105
- 101000832769 Homo sapiens Disintegrin and metalloproteinase domain-containing protein 9 Proteins 0.000 claims description 49
- 102100024361 Disintegrin and metalloproteinase domain-containing protein 9 Human genes 0.000 claims description 46
- 150000003839 salts Chemical class 0.000 claims description 43
- 239000012634 fragment Substances 0.000 claims description 40
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 29
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 24
- 229910052757 nitrogen Inorganic materials 0.000 claims description 22
- 125000000539 amino acid group Chemical group 0.000 claims description 20
- 229910052799 carbon Inorganic materials 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 14
- 238000012986 modification Methods 0.000 claims description 14
- 230000004048 modification Effects 0.000 claims description 14
- 235000001014 amino acid Nutrition 0.000 claims description 13
- 150000001413 amino acids Chemical class 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 11
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 10
- 239000011734 sodium Substances 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 150000001412 amines Chemical class 0.000 claims description 8
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 5
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 3
- 206010057644 Testis cancer Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
- 201000006491 bone marrow cancer Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 102000054116 human ADAM9 Human genes 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 201000003120 testicular cancer Diseases 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 206010046766 uterine cancer Diseases 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008177 pharmaceutical agent Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 159000000000 sodium salts Chemical group 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 5
- 229910052708 sodium Inorganic materials 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 2
- 108010056243 alanylalanine Proteins 0.000 description 16
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 16
- LIWMQSWFLXEGMA-WDSKDSINSA-N Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)N LIWMQSWFLXEGMA-WDSKDSINSA-N 0.000 description 8
- DEFJQIDDEAULHB-QWWZWVQMSA-N D-alanyl-D-alanine Chemical compound C[C@@H]([NH3+])C(=O)N[C@H](C)C([O-])=O DEFJQIDDEAULHB-QWWZWVQMSA-N 0.000 description 8
- DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 description 8
- DEFJQIDDEAULHB-UHFFFAOYSA-N N-D-alanyl-D-alanine Natural products CC(N)C(=O)NC(C)C(O)=O DEFJQIDDEAULHB-UHFFFAOYSA-N 0.000 description 8
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 8
- 201000007750 congenital bile acid synthesis defect Diseases 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- KQRHTCDQWJLLME-XUXIUFHCSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)N KQRHTCDQWJLLME-XUXIUFHCSA-N 0.000 description 4
- AGGWFDNPHKLBBV-YUMQZZPRSA-N (2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoic acid Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=O AGGWFDNPHKLBBV-YUMQZZPRSA-N 0.000 description 4
- ALBODLTZUXKBGZ-JUUVMNCLSA-N (2s)-2-amino-3-phenylpropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 ALBODLTZUXKBGZ-JUUVMNCLSA-N 0.000 description 4
- RVLOMLVNNBWRSR-KNIFDHDWSA-N (2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O RVLOMLVNNBWRSR-KNIFDHDWSA-N 0.000 description 4
- WEZDRVHTDXTVLT-GJZGRUSLSA-N 2-[[(2s)-2-[[(2s)-2-[(2-aminoacetyl)amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 WEZDRVHTDXTVLT-GJZGRUSLSA-N 0.000 description 4
- FSHURBQASBLAPO-WDSKDSINSA-N Ala-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](C)N FSHURBQASBLAPO-WDSKDSINSA-N 0.000 description 4
- OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 description 4
- DAQIJMOLTMGJLO-YUMQZZPRSA-N Arg-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCNC(N)=N DAQIJMOLTMGJLO-YUMQZZPRSA-N 0.000 description 4
- SJUXYGVRSGTPMC-IMJSIDKUSA-N Asn-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O SJUXYGVRSGTPMC-IMJSIDKUSA-N 0.000 description 4
- 0 CC(C)IN*CNC(C)(C)C Chemical compound CC(C)IN*CNC(C)(C)C 0.000 description 4
- -1 D-Phe-Phe-Lys Chemical compound 0.000 description 4
- FAQVCWVVIYYWRR-WHFBIAKZSA-N Gln-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O FAQVCWVVIYYWRR-WHFBIAKZSA-N 0.000 description 4
- VHLZDSUANXBJHW-QWRGUYRKSA-N Gln-Phe Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 VHLZDSUANXBJHW-QWRGUYRKSA-N 0.000 description 4
- MRVYVEQPNDSWLH-XPUUQOCRSA-N Gln-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(N)=O MRVYVEQPNDSWLH-XPUUQOCRSA-N 0.000 description 4
- 108010009504 Gly-Phe-Leu-Gly Proteins 0.000 description 4
- YLEIWGJJBFBFHC-KBPBESRZSA-N Gly-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 YLEIWGJJBFBFHC-KBPBESRZSA-N 0.000 description 4
- VAXBXNPRXPHGHG-BJDJZHNGSA-N Ile-Ala-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)O)N VAXBXNPRXPHGHG-BJDJZHNGSA-N 0.000 description 4
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 4
- LSPYFSHXDAYVDI-SRVKXCTJSA-N Leu-Ala-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(C)C LSPYFSHXDAYVDI-SRVKXCTJSA-N 0.000 description 4
- NVGBPTNZLWRQSY-UWVGGRQHSA-N Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN NVGBPTNZLWRQSY-UWVGGRQHSA-N 0.000 description 4
- JHKXZYLNVJRAAJ-WDSKDSINSA-N Met-Ala Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(O)=O JHKXZYLNVJRAAJ-WDSKDSINSA-N 0.000 description 4
- MIDZLCFIAINOQN-WPRPVWTQSA-N Phe-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 MIDZLCFIAINOQN-WPRPVWTQSA-N 0.000 description 4
- RBRNEFJTEHPDSL-ACRUOGEOSA-N Phe-Phe-Lys Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 RBRNEFJTEHPDSL-ACRUOGEOSA-N 0.000 description 4
- HSRXSKHRSXRCFC-WDSKDSINSA-N Val-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(O)=O HSRXSKHRSXRCFC-WDSKDSINSA-N 0.000 description 4
- QRZVUAAKNRHEOP-GUBZILKMSA-N Val-Ala-Val Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O QRZVUAAKNRHEOP-GUBZILKMSA-N 0.000 description 4
- IBIDRSSEHFLGSD-YUMQZZPRSA-N Val-Arg Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IBIDRSSEHFLGSD-YUMQZZPRSA-N 0.000 description 4
- JKHXYJKMNSSFFL-IUCAKERBSA-N Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN JKHXYJKMNSSFFL-IUCAKERBSA-N 0.000 description 4
- 208000009956 adenocarcinoma Diseases 0.000 description 4
- 108010054982 alanyl-leucyl-alanyl-leucine Proteins 0.000 description 4
- 108010068380 arginylarginine Proteins 0.000 description 4
- 108010036533 arginylvaline Proteins 0.000 description 4
- 108010054155 lysyllysine Proteins 0.000 description 4
- 108010024607 phenylalanylalanine Proteins 0.000 description 4
- IBIDRSSEHFLGSD-UHFFFAOYSA-N valinyl-arginine Natural products CC(C)C(N)C(=O)NC(C(O)=O)CCCN=C(N)N IBIDRSSEHFLGSD-UHFFFAOYSA-N 0.000 description 4
- 108010073969 valyllysine Proteins 0.000 description 4
- 108010039491 Ricin Proteins 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 description 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 2
- 208000018142 Leiomyosarcoma Diseases 0.000 description 2
- 208000022136 colorectal lymphoma Diseases 0.000 description 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- QLWSUEDEGARQCO-UHFFFAOYSA-N CCC(CC(N1CCNC(CCNC(CNC(CNC(CNC(CCCN(C(CC2C)=O)C2=O)=O)=O)=O)=O)=O)=O)C1=O Chemical compound CCC(CC(N1CCNC(CCNC(CNC(CNC(CNC(CCCN(C(CC2C)=O)C2=O)=O)=O)=O)=O)=O)=O)C1=O QLWSUEDEGARQCO-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662438488P | 2016-12-23 | 2016-12-23 | |
| US62/438,488 | 2016-12-23 | ||
| US201762480201P | 2017-03-31 | 2017-03-31 | |
| US62/480,201 | 2017-03-31 | ||
| PCT/US2017/067823 WO2018119196A1 (en) | 2016-12-23 | 2017-12-21 | Immunoconjugates targeting adam9 and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020504607A JP2020504607A (ja) | 2020-02-13 |
| JP2020504607A5 true JP2020504607A5 (enExample) | 2021-02-04 |
| JP7170642B2 JP7170642B2 (ja) | 2022-11-14 |
Family
ID=61025051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019533514A Active JP7170642B2 (ja) | 2016-12-23 | 2017-12-21 | Ａｄａｍ９を標的とする免疫コンジュゲート及びその使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20210388102A1 (enExample) |
| EP (1) | EP3558391B1 (enExample) |
| JP (1) | JP7170642B2 (enExample) |
| CN (1) | CN110267685B (enExample) |
| CY (1) | CY1125181T1 (enExample) |
| DK (1) | DK3558391T3 (enExample) |
| ES (1) | ES2912266T3 (enExample) |
| HR (1) | HRP20220550T1 (enExample) |
| HU (1) | HUE058664T2 (enExample) |
| LT (1) | LT3558391T (enExample) |
| MD (1) | MD3558391T2 (enExample) |
| PL (1) | PL3558391T3 (enExample) |
| PT (1) | PT3558391T (enExample) |
| RS (1) | RS63154B1 (enExample) |
| SI (1) | SI3558391T1 (enExample) |
| SM (1) | SMT202200182T1 (enExample) |
| TW (1) | TWI783957B (enExample) |
| WO (1) | WO2018119196A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA51629A (fr) | 2018-01-12 | 2020-11-18 | Immunogen Inc | Procédés de production, purification et formulation de conjugués anticorps-médicaments |
| KR20210061995A (ko) * | 2018-06-26 | 2021-05-28 | 이뮤노젠 아이엔씨 | Adam9를 표적으로 하는 면역콘쥬게이트 및 이를 이용하는 방법들 |
| KR20220022112A (ko) * | 2019-03-21 | 2022-02-24 | 이뮤노젠 아이엔씨 | 세포-결합 제제-약물 콘쥬게이트를 준비하는 방법 |
| TW202102506A (zh) | 2019-03-29 | 2021-01-16 | 美商伊繆諾金公司 | 苯二氮平衍生物 |
| PT3958977T (pt) | 2019-04-26 | 2023-12-15 | Immunogen Inc | Derivados de camptotecina |
| CN110713983B (zh) * | 2019-11-04 | 2022-06-10 | 深圳市体内生物医药科技有限公司 | 一种表达透明质酸酶的免疫细胞及其应用 |
| CN117729942A (zh) | 2021-03-08 | 2024-03-19 | 伊缪诺金公司 | 用于增加靶向adam9的免疫缀合物治疗癌症的功效的方法 |
| CN118684724A (zh) | 2023-03-22 | 2024-09-24 | 映恩生物制药（苏州）有限公司 | 连接子及其在配体药物偶联物中的应用 |
| TW202438113A (zh) * | 2023-03-24 | 2024-10-01 | 大陸商映恩生物製藥（蘇州）有限公司 | 標靶ａｄａｍ９的人源化抗體、其抗體藥物偶聯物及其應用 |
| WO2025094146A1 (en) | 2023-11-02 | 2025-05-08 | Immunogen Switzerland Gmbh | Vasconstrictors for reducing ocular toxicity of antibody-maytansinoid conjugates |
| CN120058950A (zh) * | 2023-11-28 | 2025-05-30 | 昆山新蕴达生物科技有限公司 | 抗adam9的抗体及其用途 |
| WO2025124443A1 (zh) * | 2023-12-14 | 2025-06-19 | 四川科伦博泰生物医药股份有限公司 | Adam9结合蛋白及其用途 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| CA2078539C (en) | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| MXPA02007733A (es) | 2000-02-11 | 2004-09-10 | Merck Patent Gmbh | Mejoramiento de la vida media circulante de proteinas de fusion basadas en anticuerpos. |
| US20030091568A1 (en) | 2000-04-07 | 2003-05-15 | Jurgen Frey | Inhibitors for the formation of soluble human CD23 |
| EP1142910A1 (en) | 2000-04-07 | 2001-10-10 | Jürgen Prof. Dr. Frey | Inhibitors for the formation of soluble human CD23 |
| AU2002248184C1 (en) | 2000-12-12 | 2018-01-04 | Board Of Regents, The University Of Texas System | Molecules with extended half-lives, compositions and uses thereof |
| BR0207310A (pt) | 2001-12-18 | 2004-08-17 | Mondobiotech Sa | Composição farmacêutica de interferon gama ou de pirfenidona com diagnósticos moleculares para o melhor tratamento de doenças pulmonares intersticiais |
| US6716821B2 (en) | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
| US20040092466A1 (en) | 2002-11-11 | 2004-05-13 | Isis Pharmaceuticals Inc. | Modulation of ADAM9 expression |
| EP1542723B1 (en) | 2002-08-16 | 2011-02-23 | ImmunoGen, Inc. | Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| DE10337368A1 (de) * | 2003-08-08 | 2005-03-03 | Technische Universität Dresden | Verfahren und Mittel zur Diagnose und Behandlung von Pankreastumoren |
| AU2004290070A1 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto |
| WO2005091823A2 (en) | 2004-03-01 | 2005-10-06 | The Regents Of The University Of California | The use of lunasin peptide as a transcriptional activator to prevent cancer and related methods for treatment, monitoring and prognosis |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| WO2006084075A2 (en) | 2005-02-02 | 2006-08-10 | Raven Biotechnologies, Inc. | Adam-9 modulators |
| US8445198B2 (en) | 2005-12-01 | 2013-05-21 | Medical Prognosis Institute | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| JP2009538629A (ja) | 2006-05-30 | 2009-11-12 | ジェネンテック・インコーポレーテッド | 抗体およびイムノコンジュゲートとこれらの使用方法 |
| WO2007143752A2 (en) | 2006-06-09 | 2007-12-13 | The Regents Of The University Of California | Targets in breast cancer for prognosis or therapy |
| KR101443214B1 (ko) | 2007-01-09 | 2014-09-24 | 삼성전자주식회사 | 폐암 환자 또는 폐암 치료를 받은 폐암 환자의 폐암 재발 위험을 진단하기 위한 조성물, 키트 및 마이크로어레이 |
| EP2019104B1 (en) | 2007-07-19 | 2013-09-04 | Sanofi | Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use |
| GB2453589A (en) | 2007-10-12 | 2009-04-15 | King S College London | Protease inhibition |
| WO2009114532A2 (en) | 2008-03-10 | 2009-09-17 | National Jewish Health | Markers for diagnosis of pulmonary inflammation and methods related thereto |
| AU2009233899A1 (en) | 2008-04-07 | 2009-10-15 | Zymogenetics, Inc. | Thrombin activator compostions and methods of making and using the same |
| US20090285840A1 (en) * | 2008-04-29 | 2009-11-19 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Methods for treating pathological neovascularization |
| KR20210005318A (ko) | 2008-04-30 | 2021-01-13 | 이뮤노젠 아이엔씨 | 가교제 및 그 용도 |
| WO2009134952A2 (en) | 2008-04-30 | 2009-11-05 | Immunogen, Inc | Potent conjugates and hydrophilic linkers |
| US20110081347A1 (en) | 2008-06-04 | 2011-04-07 | Macrogenics, Inc. | Antibodies with Altered Binding to FcRn and Methods of Using Same |
| WO2010014990A2 (en) | 2008-08-01 | 2010-02-04 | The Board Of Trustees Of The University Of Illinois | Method of promoting neurogenesis by modulating secretase activities |
| GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
| WO2010053539A2 (en) | 2008-11-05 | 2010-05-14 | The Texas A&M University System | Methods for detecting colorectal diseases and disorders |
| RU2011127198A (ru) | 2008-12-04 | 2013-01-10 | Эбботт Лэборетриз | Иммуноглобулины с двойными вариабельными доменами и их применение |
| JP5977522B2 (ja) | 2009-02-05 | 2016-08-24 | イミュノジェン・インコーポレーテッド | 新規ベンゾジアゼピン誘導体 |
| KR102444399B1 (ko) | 2009-06-03 | 2022-09-16 | 이뮤노젠 아이엔씨 | 메이탄시노이드의 제조방법 |
| WO2011100362A1 (en) | 2010-02-11 | 2011-08-18 | University Of Southern California | Modified adam disintegrin domain polypeptides and uses thereof |
| PT2542256T (pt) | 2010-03-04 | 2019-09-05 | Macrogenics Inc | Anticorpos reativos com b7-h3, fragmentos imunologicamente ativos dos mesmos e sua utilização |
| JP5875083B2 (ja) | 2010-04-15 | 2016-03-02 | メディミューン リミテッド | 増殖性疾患治療用ピロロベンゾジアゼピン |
| TWI617555B (zh) | 2011-02-15 | 2018-03-11 | 免疫原公司 | 細胞毒性苯并二氮呯衍生物 |
| UA116189C2 (uk) * | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| US20130058947A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc | Novel Modulators and Methods of Use |
| US20130130355A1 (en) | 2011-09-28 | 2013-05-23 | Armune Biosciences, Inc. | Method and system of particle-phage epitope complex |
| US20140342946A1 (en) | 2011-12-31 | 2014-11-20 | Moni Abraham Kuriakose | Diagnostic tests for predicting prognosis, recurrence, resistance or sensitivity to therapy and metastatic status in cancer |
| US9534058B2 (en) | 2012-02-08 | 2017-01-03 | Abbvie Stemcentrx Llc | Anti-CD324 monoclonal antibodies and uses thereof |
| WO2013177481A1 (en) | 2012-05-25 | 2013-11-28 | Immunogen, Inc. | Benzodiazepines and conjugates thereof |
| WO2014108480A1 (en) | 2013-01-09 | 2014-07-17 | Friedrich-Alexander-Universitaet Erlangen-Nuernberg | Method for in vitro detection and monitoring of a disease by measuring disease-associated protease activity in extracellular vesicles |
| CA2900764A1 (en) | 2013-02-08 | 2014-08-14 | Stemcentrx, Inc. | Novel multispecific constructs |
| JPWO2014168154A1 (ja) | 2013-04-08 | 2017-02-16 | 三菱レイヨン株式会社 | 眼疾患を評価するためのマイクロアレイ及び眼疾患の評価方法 |
| WO2014186364A2 (en) | 2013-05-13 | 2014-11-20 | Tufts University | Methods and compositions for prognosis, diagnosis and treatment of adam8-expressing cancer |
| CA2915823A1 (en) | 2013-06-19 | 2014-12-24 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for the diagnosis, prognosis and treatment of brain metastasis |
| US9567641B2 (en) | 2013-07-03 | 2017-02-14 | Samsung Electronics Co., Ltd. | Combination therapy for the treatment of cancer using an anti-C-met antibody |
| RU2017110068A (ru) * | 2014-09-03 | 2018-10-03 | Иммуноджен, Инк. | Конъюгаты, содержащие клеточносвязывающие агенты и цитотоксические агенты |
| JP2017527562A (ja) | 2014-09-03 | 2017-09-21 | イミュノジェン・インコーポレーテッド | 細胞毒性ベンゾジアゼピン誘導体 |
| DK3189056T3 (da) | 2014-09-03 | 2020-09-14 | Immunogen Inc | Cytotoksiske benzodiazepinderivater |
| CA2964968A1 (en) | 2014-11-11 | 2016-05-19 | Amunix Operating Inc. | Targeted xten conjugate compositions and methods of making same |
| CN113769108B (zh) | 2015-06-29 | 2024-11-08 | 伊缪诺金公司 | 半胱氨酸工程化抗体的结合物 |
-
2017
- 2017-12-21 PL PL17835533T patent/PL3558391T3/pl unknown
- 2017-12-21 WO PCT/US2017/067823 patent/WO2018119196A1/en not_active Ceased
- 2017-12-21 EP EP17835533.5A patent/EP3558391B1/en active Active
- 2017-12-21 PT PT178355335T patent/PT3558391T/pt unknown
- 2017-12-21 US US16/469,494 patent/US20210388102A1/en not_active Abandoned
- 2017-12-21 LT LTEPPCT/US2017/067823T patent/LT3558391T/lt unknown
- 2017-12-21 TW TW106145085A patent/TWI783957B/zh active
- 2017-12-21 HU HUE17835533A patent/HUE058664T2/hu unknown
- 2017-12-21 DK DK17835533.5T patent/DK3558391T3/da active
- 2017-12-21 SI SI201731135T patent/SI3558391T1/sl unknown
- 2017-12-21 ES ES17835533T patent/ES2912266T3/es active Active
- 2017-12-21 CN CN201780079982.XA patent/CN110267685B/zh active Active
- 2017-12-21 MD MDE20191243T patent/MD3558391T2/ro unknown
- 2017-12-21 HR HRP20220550TT patent/HRP20220550T1/hr unknown
- 2017-12-21 SM SM20220182T patent/SMT202200182T1/it unknown
- 2017-12-21 RS RS20220395A patent/RS63154B1/sr unknown
- 2017-12-21 JP JP2019533514A patent/JP7170642B2/ja active Active
-
2022
- 2022-04-27 CY CY20221100306T patent/CY1125181T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020504607A5 (enExample) | ||
| CN101903403B (zh) | Cd19结合剂及其应用 | |
| JP7585230B2 (ja) | バイパラトピックＦＲ－α抗体及びイムノコンジュゲート | |
| JP2023100903A (ja) | 多価メディトープ、メディトープ結合性抗体およびそれらの使用 | |
| US12357701B2 (en) | Anti-HER2 biparatopic antibody-drug conjugates and methods of use | |
| JP2014516508A (ja) | 抗体−薬剤コンジュゲート | |
| RU2019129839A (ru) | Производные майтанзиноида с саморасщепляющимися пептидными линкерами и их конъюгаты | |
| KR20210102334A (ko) | 트랜스글루타미나제 접합을 위해 변형된 항체, 그의 접합체, 및 방법 및 용도 | |
| JP2020532523A (ja) | 抗ｅｇｆｒ抗体薬物コンジュゲート（ａｄｃ）及びその使用 | |
| JP6377601B2 (ja) | 抗ｃｄｈ３ヒト化抗体、その薬剤コンジュゲート、及びそれらの使用 | |
| TW202540197A (zh) | 以結合191p4d12蛋白質之抗體藥物結合物(adc)治療癌症 | |
| TW201739472A (zh) | 抗磷脂醯肌醇蛋白聚糖-3抗體及妥布賴森(tubulysin)類似物之抗體藥物結合物、製備及用途 | |
| JPWO2020086665A5 (enExample) | ||
| JP2020532543A (ja) | 抗ｅｇｆｒ抗体薬物コンジュゲート（ａｄｃ）及びその使用 | |
| JPWO2020005945A5 (enExample) | ||
| JP2022513686A (ja) | グルタミンを含有する軽鎖ｃ末端に伸長部分を含む抗体およびそのコンジュゲートならびにその方法および用途 | |
| RU2832083C2 (ru) | Бипаратопные fr-альфа антитела и иммуноконъюгаты | |
| RU2021100667A (ru) | Иммуноконъюгаты, нацеленные на adam9, и способы их применения | |
| TW202535480A (zh) | 抗cd24抗體藥物結合物及其用途 | |
| WO2025183075A1 (ja) | 抗ｃｄｈ３ヒト化抗体及びそれらの使用 | |
| JP2026501556A (ja) | 抗体薬物複合体 | |
| RU2023128710A (ru) | Антитела против c-met и коньюгаты антитела с лекарственным средством | |
| RU2025107388A (ru) | Антитела к trop2/egfr и пути их применения | |
| HK40041667A (en) | Anti-her2 biparatopic antibody-drug conjugates and methods of use |